急性早幼粒细胞白血病
医学
癌症
药物输送
癌症研究
癌症治疗
维甲酸
癌细胞
药理学
生物信息学
生物
化学
内科学
细胞培养
遗传学
有机化学
作者
Maria Valeria Giuli,Patrizia Nadia Hanieh,Eugenia Giuliani,Federica Rinaldi,Carlotta Marianecci,Isabella Screpanti,Saula Checquolo,Maria Carafa
出处
期刊:Pharmaceutics
[MDPI AG]
日期:2020-07-28
卷期号:12 (8): 707-707
被引量:22
标识
DOI:10.3390/pharmaceutics12080707
摘要
All-Trans Retinoic Acid (ATRA) is the most active metabolite of vitamin A. It is critically involved in the regulation of multiple processes, such as cell differentiation and apoptosis, by activating specific genomic pathways or by influencing key signaling proteins. Furthermore, mounting evidence highlights the anti-tumor activity of this compound. Notably, oral administration of ATRA is the first choice treatment in Acute Promyelocytic Leukemia (APL) in adults and NeuroBlastoma (NB) in children. Regrettably, the promising results obtained for these diseases have not been translated yet into the clinics for solid tumors. This is mainly due to ATRA-resistance developed by cancer cells and to ineffective delivery and targeting. This up-to-date review deals with recent studies on different ATRA-loaded Drug Delivery Systems (DDSs) development and application on several tumor models. Moreover, patents, pre-clinical, and clinical studies are also reviewed. To sum up, the main aim of this in-depth review is to provide a detailed overview of the several attempts which have been made in the recent years to ameliorate ATRA delivery and targeting in cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI